NCT06428097View on ClinicalTrials.gov

Levothyroxine Supplementation for Heart Transplant Recipients

PHASE1RecruitingINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

March 29, 2024

Primary Completion Date

March 1, 2027

Study Completion Date

March 1, 2027

Conditions
Heart Transplant FailureHeart Transplant Infection
Interventions
DRUG

Levothyroxine

Dosing will be based on pre-existing protocols in the setting of organ donation.This will be the protocol for the first 18-38 hours starting intra-operatively after the donated heart is sewn in.

DRUG

Normal saline

Placebo will be normal saline and will be dosed at the same rate and time as the study drug.

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER